Africa-Press – Cape verde. Last Friday, the 8th, the Independent Health Regulatory Authority (ERIS) released an informative circular on the stock out of the drug methotrexate (indicated for the treatment of cancer) and recommended that importers and distributors, doctors, pharmacists and patients, take measures to mitigate the impact of the situation.
The ERIS circular highlights that the entity was notified of the drug’s rupture and immediately began the procedure to monitor the situation, aiming to stabilize it and ensuring the effective communication of relevant information to all parties involved.
The entity recommends that importers and distributors adopt precautionary measures in order to avoid stock-outs of medicines, considering the response time of suppliers.
It also recommends evaluating the need to reinforce the safety stock of the drug targeted for rupture, considering the delay in response from suppliers and continuing to make data on the situation available to everyone involved in the process.
For healthcare professionals, ERIS recommends keeping users duly informed about the rupture and assessing the need to replace therapy and adopt other applicable measures.
For users, the entity suggests contacting the attending physician in good time to assess the need to replace therapy with methotrexate.
It should be noted that methotrexate is indicated in the treatment of neoplastic diseases such as choriocarcinoma, chorioadenoma destruens, hydatidiform mole, acute lymphoblastic leukemia, breast cancer, epidermoid cancers of the head and neck, mycosis fungoides (cutaneous T-cell lymphoma), lung cancer, non-Hodgkin lymphoma and osteosarcoma. It is also indicated for the treatment of psoriasis and rheumatoid arthritis, including polyarticular juvenile idiopathic arthritis, when these manifest themselves in a severe, recalcitrant and disabling form.
For More News And Analysis About Cape verde Follow Africa-Press
